Filing Flows › TScan Therapeutics (TCRX) › R&D spending
TScan Therapeutics (TCRX) R&D spending by quarter
TScan Therapeutics' R&D spending was $23.4M in Q2 2026 (second quarter 2026), +7% from Q1 2026. Over the last 7 quarters it ranged from $20.0M (Q4 2025) to $32.6M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $23.4M | +7% | -28% |
| Q1 2026 | $21.9M | +9% | -26% |
| Q4 2025 | $20.0M | -37% | -32% |
| Q3 2025 | $31.7M | -3% | — |
| Q2 2025 | $32.6M | +10% | — |
| Q1 2025 | $29.8M | +1% | — |
| Q4 2024 | $29.4M | — | — |
Q2 2026 at a glance
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is TScan Therapeutics' R&D spending?
TScan Therapeutics' R&D spending was $23.4M in Q2 2026 (second quarter 2026), +7% from Q1 2026.
How has TScan Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $20.0M (Q4 2025) to $32.6M (Q2 2025).